Duchenne muscular dystrophy
BioMarin to Present at the Barclays Capital Global Healthcare Conference
...treatment of MPS IVA and BMN 195, which is currently in Phase I clinical development for the treatment of Duchenne Muscular Dystrophy. For additional information, please visit www.
Chemical that 'protects' hearts of muscular dystrophy patients discovered
...Medical School scientists have discovered a chemical that may, over the long term, protect the hearts of Duchenne muscular dystrophy patients - a fatal and most common form of...
JavaScript and Flash are required to fully enjoy Evri
Researchers discover chemical that may protect hearts of muscular dystrophy patients
...of Minnesota Medical School have discovered a chemical that may, over the long term, protect the hearts of Duchenne muscular dystrophy patients -- a fatal and most common form of muscular...
Rare diseases causing needless deaths, says Sir Liam Donaldson
...research suggests. The European Organisation for Rare Diseases found that more than a third of cases of Duchenne muscular dystrophy are initially misdiagnosed and almost 40 per cent of...
Idol Headlines for 03/13/10 - The Afternoon Edition
...High School teamed with four professionals from Tinley Park's Heart and Sole Dance school to raise money for the Duchenne Muscular Dystrophy organization. The judges were Oak Lawn High...
Honey, Don't Bother Mommy. I'm Too Busy Building My Brand.
...and road-tripped to Disney World in a Chevy Traverse, courtesy of G. M. Canada, to help raise awareness about Duchenne's muscular dystrophy. But just as some cringe at Tupperware...
AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Corporate Update Conference Call
...of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy, including an ongoing systemic Phase 1b/2 clinical...
PTC Therapeutics and Genzyme Corporation Announce Preliminary Results from the Phase 2b Clinical Trial of Ataluren for Nonsense Mutation Duchenne/Becker Muscular Dystrophy
Dystrophin is critical to the structural stability of skeletal, diaphragm, and heart muscles. Patients with Duchenne muscular dystrophy, the more severe form of the disorder, may lose the...
Jorn Aldag, Chief Executive Officer of AMT, commented: "In 2009 we announced a rebalancing of our strategy, focused on our lead product Glybera(R), a proprietary product for lipoprotein lipase deficiency (LPLD), together with the ongoing development of four earlier stage progams targeting: Hemophilia B, Duchenne Muscular Dystrophy (DMD), Acute Intermittent Porphyria (AIP) and Parkinson's Disease. At the end of 2009 we reached a major milestone by submitting the Marketing Authorisation Application (MAA) for Glybera(R) to the European Medicine Agency (EMA), and this dossier was validated by EMA on January 20, 2010. After having de-risked our business model and secured funding into 2011 we are well positioned for the future."
Amsterdam Molecular Therapeutics Reports Full Year Results 2009 Fox News | 3 weeks ago
Hope For Muscular Dystrophy Patients?
...is a senior editor at Forbes Clinical trial results are due out soon that could give hope to some patients with Duchenne muscular dystrophy, a rare genetic disorder that robs boys of...
Dublin Boy Gets Service Dog Donated
Thursday, February 25, 2010 2:48 PM DUBLIN, Ohio - A boy suffering from Duchenne muscular dystrophy on Thursday received some help from a new four-legged friend. Milk Bone donated a...
Amsterdam Molecular Therapeutics Reports Full Year Results 2009
...(LPLD), together with the ongoing development of four earlier stage progams targeting: Hemophilia B, Duchenne Muscular Dystrophy (DMD), Acute Intermittent Porphyria (AIP) and...
Genzyme Reports Financial Results for Fourth Quarter of 2009 and Full Year
...of genetic disorders due to nonsense mutations. Results of a pivotal phase 2b trial of ataluren in Duchenne muscular dystrophy are anticipated during the first half of this year, a...

clemsontigers.cstv.com

